Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the importance of recognizing adverse drug reactions, methods of prevention, and encourages reporting them to the FDA's MedWatch program; it reports no new results.

In this review, the authors highlight the FDA approval of Ritlecitinib, the first oral treatment specifically for moderate to severe alopecia areata in patients aged 12 and older, marking a significant advancement in managing this condition.

This narrative review discusses adverse effects associated with 5-ARI treatments for male-pattern baldness and benign prostate hyperplasia, including sexual health, neurological, endocrine, metabolic, and cardiovascular impacts, and emphasizes careful prescription assessment.

In this study, researchers found that RORA directly regulates the expression of the Bnip3 gene, which is crucial for hair follicle stem cell health, using rat HFSCs as a model. They propose that targeting RORA could modulate HFSC status.

In this systematic review, animal studies showed that cytarabine causes multi-organ toxicities, notably neurotoxicity, linked to oxidative stress and other mechanisms, though study quality raises concerns about reliability and translation to human outcomes.

This study reports that ritlecitinib 50 mg, with or without an initial loading dose, demonstrated meaningful and sustained efficacy up to 24 months in the Asian subpopulation with severe alopecia areata, showing significant scalp, eyebrow, and eyelash hair regrowth, along with an acceptable safety profile.

In laboratory tests, this study found that a novel natural composition targeting 5-alpha reductase and inflammatory pathways reduced disease-related markers in androgenetic alopecia and benign prostatic hyperplasia more effectively than finasteride.

In this study, a new formulation of all-trans retinoic acid bound to polyvinyl alcohol showed reduced skin inflammation and sustained drug release for up to six days compared to free ATRA in vitro and in vivo.

In this study, researchers using Arabidopsis thaliana found that adenosine may inhibit root hair growth and stomatal opening, suggesting it plays a signaling role in plants similar to its function in animal cells, potentially revealing a new adenosine-like receptor pathway.

This study found that a short-term treatment with all-trans retinoic acid may effectively stabilize platelet counts in idiopathic thrombocytopenic purpura patients experiencing fluctuations during thrombopoietin receptor agonist therapy.

In this study, the authors developed a novel PROTAC named dAR-6–1, which demonstrated superior hair regeneration in an AGA mouse model compared to minoxidil, highlighting its promise as a therapy due to potent AR degradation and excellent skin permeability.

In a hair-growth mouse model, this study reported that the novel AR antagonist candidate 39, derived from structural optimization of 14-P1, achieved similar efficacy to pyrilutamide with faster response and maintained safety, demonstrating potent AR antagonism and favorable pharmacokinetics with lower systemic toxicity risk.

This study investigated AHR signaling's role in skin biology and reported that novel AHR ligands may help restore keratinocyte function and reduce inflammation in skin diseases, suggesting their potential as therapeutic agents.

This study found that in Asian patients aged 12 and older with alopecia areata and significant hair loss, ritlecitinib showed clinical efficacy in improving hair regrowth and eyebrow and eyelash scores over 48 weeks, with an acceptable safety profile observed throughout.

This study identified potential new adverse drug reaction signals for erlotinib, used in lung and pancreatic cancer treatment, by analyzing a large dataset of case reports, indicating further clinical studies are necessary to confirm these findings.

This study identifies a mechanism where dsRNA activates TLR3 to induce RA production, promoting hair follicle regeneration in mice and suggesting a potential role in human tissue regeneration.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

This study found that Ocimum basilicum L. showed the highest 5α-reductase inhibitory activity among ten Thai plants, despite no correlation between enzyme inhibition and total phenolic content.

This review discusses the traditional uses, phytochemistry, and pharmacological activities of Curcuma aeruginosa Roxb., highlighting its potential as a source for therapeutic applications and drug development, but it reports no new clinical results.

This study found that AR-007 degrades faster and has a stronger association with hsp70 than AR-014, suggesting it is less stable when bound to the androgen receptor.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.

This protocol outlines a planned Cochrane Review to evaluate the effects of 5-alpha-reductase inhibitors on lower urinary tract symptoms caused by benign prostatic obstruction, and it reports no new findings.

This study found that coffee extraction and its active compound, caffeotannic acid, showed high enzyme inhibition activity against 5a-reductase in an in vitro model.

This study found that novel compounds moderately inhibited 5α-reductase type 1 activity compared to finasteride, offering valuable data on structure-activity relationships.

This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

This review discusses the pharmacology of 5-alpha reductase inhibitors, their expanding clinical indications beyond benign prostatic hyperplasia, and notes unresolved claims about their potential role in SARS-CoV-2.

This study found that minoxidil suppressed androgen receptor functions and stability, suggesting its potential use in treating diseases related to the androgen-AR pathway.

This review by Aceituno et al. found that both baricitinib and ritlecitinib demonstrate strong efficacy for severe alopecia areata, with meaningful hair regrowth by Week 24, but notes limitations like differing trial sizes and potential effect size overestimations.